CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts

CD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces tumour growth and that this effect is associated to induction of growth-inhibiting factors. Moreover, treatment with this antibody prevents tumour relapse after chemotherapy-induced remission in a basal-like HBCx

Is information on boards useful for investors’ appraisal of a firm's value?

This article examines if investors rely on certain information about board characteristics appearing in circulars, to appraise a firm’s market value. The board traits considered in the study are independence, size, ratio of equity remuneration to total director remuneration, board ownership and director tenure. Our results show that the ratio of equity remuneration to total remuneration and director tenure are positively connected with firm market capitalization. Director ownership, however, appears to be negatively correlated with firm valuation

Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion

10.1007/s00280-008-0684-zCancer Chemotherapy and Pharmacology626949-95